VCYT Stock Overview
Veracyte, Inc. operates as a diagnostics company in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Veracyte, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$21.72 |
52 Week High | US$30.52 |
52 Week Low | US$19.52 |
Beta | 1.63 |
1 Month Change | -7.81% |
3 Month Change | -24.11% |
1 Year Change | 1.16% |
3 Year Change | -59.59% |
5 Year Change | -12.35% |
Change since IPO | 63.92% |
Recent News & Updates
Recent updates
Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S
Apr 18A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)
Mar 18Veracyte Percepta Genomic Sequencing Classifier demonstrates accuracy in lung cancer risk
Jul 13Veracyte: Not A Healthy Diagnosis
May 12Valuing Veracyte Stock
Oct 03Shareholder Returns
VCYT | US Biotechs | US Market | |
---|---|---|---|
7D | 0.5% | 0.9% | 0.4% |
1Y | 1.2% | 10.3% | 28.8% |
Return vs Industry: VCYT underperformed the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: VCYT underperformed the US Market which returned 29.5% over the past year.
Price Volatility
VCYT volatility | |
---|---|
VCYT Average Weekly Movement | 7.5% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VCYT's share price has been volatile over the past 3 months.
Volatility Over Time: VCYT's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 815 | Marc Stapley | https://www.veracyte.com |
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test.
Veracyte, Inc. Fundamentals Summary
VCYT fundamental statistics | |
---|---|
Market cap | US$1.63b |
Earnings (TTM) | -US$74.40m |
Revenue (TTM) | US$361.05m |
4.5x
P/S Ratio-21.9x
P/E RatioIs VCYT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VCYT income statement (TTM) | |
---|---|
Revenue | US$361.05m |
Cost of Revenue | US$112.90m |
Gross Profit | US$248.15m |
Other Expenses | US$322.55m |
Earnings | -US$74.40m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.99 |
Gross Margin | 68.73% |
Net Profit Margin | -20.61% |
Debt/Equity Ratio | 0% |
How did VCYT perform over the long term?
See historical performance and comparison